RARE Stock Cash Flow Statements

Ultragenyx Pharmaceutical Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Ultragenyx Pharmaceutical Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-30	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31

operating activities:
net income	-114,951,000	-151,080,000	-133,385,000	-133,516,000	-131,598,000	-170,684,000	-123,190,000	-159,649,000	-159,828,000	-163,972,000	-151,833,000	-245,106,000	-158,162,000	-152,320,000	-122,458,000	-72,998,000	-122,428,000	-136,141,000	-24,011,000	-68,845,000	25,315,000	-119,025,000	-93,805,000	-112,994,000	-99,172,000	-96,756,000	-87,826,000	-87,310,000	-52,728,000	30,253,000	-81,731,000	-79,227,000	-72,891,000	-68,290,000	-71,287,000	-64,907,000	-56,923,000	-52,757,000	-55,220,000	-39,232,000	-29,787,000	-21,379,000	-16,738,000	-15,849,000	-13,585,000	-13,630,000
adjustments to reconcile net income to net cash from operating activities:
stock-based compensation	38,529,000	39,917,000	40,164,000	41,569,000	39,371,000	36,926,000	33,744,000	34,877,000	34,654,000	31,952,000	29,355,000	35,762,000	35,864,000	29,396,000	26,819,000	26,788,000	27,091,000	24,254,000	22,838,000	20,339,000	22,403,000	20,155,000	19,660,000	19,907,000	22,207,000	20,221,000	21,080,000	20,667,000	19,563,000	18,797,000	19,541,000	17,180,000	16,794,000	14,499,000	13,538,000	13,694,000	10,860,000	10,217,000	9,489,000	7,896,000	5,091,000	2,408,000	2,001,000	1,652,000	946,000	795,000
amortization of discount on marketable debt securities	-1,047,000	-1,733,000		-3,115,000	-2,947,000	-3,756,000
depreciation and amortization	8,619,000	8,990,000	9,079,000	8,757,000	8,862,000	8,845,000	8,218,000	7,191,000	5,361,000	5,236,000	4,957,000	4,694,000	4,481,000	4,088,000	3,534,000	3,217,000	3,121,000	3,367,000	3,133,000	3,092,000	3,184,000	2,852,000	2,169,000	2,145,000	2,106,000	2,119,000	2,943,000	4,355,000	6,080,000	6,160,000	2,514,000	1,095,000	1,055,000	1,161,000	1,157,000	1,031,000	692,000	544,000	480,000	441,000	262,000	201,000	212,000	194,000	161,000	117,000
non-cash royalty revenue	-30,321,000	-19,187,000		-23,054,000	-26,289,000	-18,063,000		-20,543,000	-17,270,000	-4,882,000
non-cash interest expense on liabilities for sales of future royalties	14,041,000	14,342,000	15,522,000	15,712,000	15,960,000	15,847,000	17,328,000	17,665,000	15,375,000	15,636,000
other	-1,172,000	-1,248,000	757,000	-3,498,000	-671,000	-77,000	-802,000	1,047,000	1,868,000	187,000	-794,000	178,000	351,000	35,000	-198,000	-78,000	186,000	325,000	1,195,000	-62,000			337,000	352,000			-11,000	0
changes in operating assets and liabilities:
accounts receivable	-12,653,000	10,062,000	-20,640,000	9,792,000	2,158,000	-24,908,000	1,012,000	-6,204,000	-15,078,000	-2,508,000	-9,095,000	5,929,000	-8,935,000	33,000	-3,070,000	-693,000	324,000	-1,993,000	4,714,000	-12,829,000	14,455,000	3,500,000	-9,702,000	-2,241,000	-5,262,000	-2,899,000	1,572,000
inventory	208,000	-763,000	-2,456,000	-2,500,000	-4,127,000	-2,124,000	-1,956,000	-3,467,000	-1,657,000	150,000	-4,205,000	-791,000	-3,230,000	-1,475,000	-990,000	47,000	-2,648,000	474,000	1,289,000	-3,156,000	372,000	149,000	2,153,000	-564,000	-2,393,000	-3,647,000
prepaid expenses and other assets	313,000	-17,478,000						4,990,000	12,113,000	-519,000	3,240,000	7,351,000	-15,919,000	9,126,000	-22,529,000	2,023,000	1,654,000	-10,656,000	15,209,000	-6,325,000	8,960,000	-15,096,000
accounts payable, accrued, and other liabilities	-9,682,000	-48,454,000	46,385,000	10,818,000	25,329,000	-35,540,000	17,126,000	7,481,000	11,781,000	-34,008,000	35,026,000	11,156,000	57,424,000	-16,164,000	30,393,000	13,446,000	12,076,000	-23,602,000	24,031,000	11,655,000	-3,450,000	-5,383,000
net cash from operating activities	-108,273,000	-166,475,000	-79,503,000	-66,995,000	-76,963,000	-190,727,000	-83,904,000	-117,874,000	-116,161,000	-156,867,000	-90,342,000	-95,345,000	-77,257,000	-117,521,000	-54,344,000	-59,649,000	-65,356,000	-159,346,000	-62,452,000	-61,967,000	87,351,000	-95,152,000	-72,039,000	-88,506,000	-89,063,000	-95,775,000	-55,853,000	-69,157,000	-76,078,000	-89,478,000	-81,823,000	-61,993,000	-48,822,000	-61,205,000	-47,680,000	-28,745,000	-39,655,000	-44,895,000	-40,444,000	-30,601,000	-17,273,000	-17,659,000	-14,739,000	-11,030,000	-10,529,000	-8,336,000
capex	-2,460,000	-1,324,000	-654,000	-1,617,000	-2,009,000	-3,211,000	-1,600,000	-3,695,000	-13,938,000	-25,034,000	-26,970,000	-26,046,000	-30,923,000	-32,184,000	-16,048,000	-20,560,000	0	-16,414,000	0	-3,780,000	-4,083,000	-14,096,000	-11,500,000	-5,033,000	-5,240,000	-3,059,000	-1,192,000	-1,032,000	-1,377,000	-475,000	-899,000	-1,033,000	-376,000	-485,000	-666,000	-3,001,000	-5,044,000	-1,477,000	-1,923,000	-1,978,000	-595,000	-459,000	-453,000	-439,000	-688,000	-569,000
free cash flows	-110,733,000	-167,799,000	-80,157,000	-68,612,000	-78,972,000	-193,938,000	-85,504,000	-121,569,000	-130,099,000	-181,901,000	-117,312,000	-121,391,000	-108,180,000	-149,705,000	-70,392,000	-80,209,000	-65,356,000	-175,760,000	-62,452,000	-65,747,000	83,268,000	-109,248,000	-83,539,000	-93,539,000	-94,303,000	-98,834,000	-57,045,000	-70,189,000	-77,455,000	-89,953,000	-82,722,000	-63,026,000	-49,198,000	-61,690,000	-48,346,000	-31,746,000	-44,699,000	-46,372,000	-42,367,000	-32,579,000	-17,868,000	-18,118,000	-15,192,000	-11,469,000	-11,217,000	-8,905,000
investing activities:
purchase of property, plant, and equipment	-2,460,000	-1,324,000	-654,000	-1,617,000	-2,009,000	-3,211,000	-1,600,000	-3,695,000	-13,938,000	-25,034,000	-26,970,000	-26,046,000	-30,923,000	-32,184,000	-16,048,000	-20,560,000
purchase of marketable debt securities			-15,933,000	-367,379,000	-3,373,000	-21,928,000	-221,593,000	-139,484,000	-103,281,000	-62,024,000	-198,574,000	-210,883,000	-1,568,000	-203,710,000	-94,778,000	-253,062,000	-259,117,000	-405,230,000
proceeds from sale of marketable debt securities	51,000	92,000	99,000	126,000	177,000	2,845,000	3,152,000	32,893,000	3,912,000	10,715,000	1,309,000	40,016,000	3,528,000	39,422,000	9,578,000	12,770,000	55,568,000	14,980,000
proceeds from maturities of marketable debt securities	89,395,000	136,902,000	119,350,000	93,571,000	68,310,000	128,794,000	113,295,000	175,009,000	215,623,000	191,598,000	42,780,000	110,622,000	108,314,000	188,990,000	134,114,000	177,383,000	182,374,000	224,240,000
payments for intangible asset	0	-15,000,000		0
net cash from investing activities	71,175,000	119,890,000	102,735,000	-275,502,000	60,564,000	94,435,000	-107,017,000	64,295,000	99,418,000	111,304,000	-171,599,000	-161,859,000	79,168,000	-37,362,000	69,057,000	-40,759,000	-41,246,000	-182,424,000	97,901,000	-95,758,000	-86,139,000	-95,125,000	67,266,000	79,314,000	-58,426,000	-101,193,000	73,561,000	16,205,000	-52,069,000	-71,028,000	57,104,000	29,788,000	-21,076,000	-9,400,000	-8,355,000	52,509,000	23,986,000	21,775,000	-33,560,000	-143,715,000	-111,011,000	-4,065,000	-17,021,000	-13,545,000	-27,476,000	-65,398,000
financing activities:
proceeds from the issuance of common stock and pre-funded warrants in connection with the underwritten public offering				117,000
proceeds from the issuance of common stock in connection with at-the-market offering								24,792,000											0	0			0	0	5,523,000	19,305,000
proceeds from the issuance of common stock under equity plan awards, net of tax	3,921,000	157,000		4,057,000	4,073,000	-58,000		442,000	4,569,000	-750,000
net cash from financing activities	83,649,000	157,000	3,186,000	11,174,000	384,939,000	-58,000	330,610,000	25,234,000	33,020,000	-722,000	1,882,000	491,877,000	5,837,000	1,612,000	85,725,000	7,550,000	12,628,000	12,649,000	489,711,000	19,135,000	35,811,000	55,615,000	315,443,000	904,000	9,342,000	353,617,000	12,242,000	25,024,000	13,168,000	286,419,000	64,439,000	1,333,000	1,526,000	68,969,000	74,940,000	63,447,000	-25,000	314,000	887,000	288,651,000	2,595,000	175,440,000	2,697,000	60,510,000	10,000	121,754,000
effect of exchange rate changes on cash	2,914,000	1,448,000	-2,473,000	1,275,000	-648,000	-679,000	1,103,000	-716,000	-136,000	211,000	1,352,000	-1,081,000	-1,238,000	-108,000	-392,000	-479,000	448,000	-771,000	880,000	437,000	425,000	-623,000	337,000	-472,000	168,000	-198,000	145,000	30,000	-896,000	249,000	361,000	528,000	-378,000	17,000
net increase in cash, cash equivalents and restricted cash																				-138,153,000	37,448,000	-135,285,000		-8,760,000	-137,979,000	156,451,000			-115,875,000	126,162,000
cash, cash equivalents and restricted cash at beginning of period	0	184,159,000		0	0	219,399,000		0	0	137,601,000		0	0	309,585,000		0	0	726,294,000		0	0	436,244,000		0	0	115,525,000		0	0	103,041,000
cash, cash equivalents and restricted cash at end of period	49,465,000	139,179,000		-330,048,000	367,892,000	122,370,000		-29,061,000	16,141,000	91,527,000		233,592,000	6,510,000	156,206,000		-93,337,000	-93,526,000	396,402,000		-138,153,000	37,448,000	300,959,000		-8,760,000	-137,979,000	271,976,000		-27,898,000	-115,875,000	229,203,000
supplemental disclosures of non-cash information:
stock-based compensation capitalized into ending inventory	-189,000	2,999,000		198,000	218,000	2,786,000		259,000	27,000	2,276,000
costs of property, plant and equipment included in accounts payable, accrued, and other liabilities	-544,000	1,566,000			-381,000	1,280,000
change in fair value of equity investments		157,000	1,548,000	-678,000	3,991,000	-3,746,000	-1,889,000	1,419,000	-261,000	334,000	-1,840,000	1,626,000	10,184,000	9,329,000	16,100,000	-25,702,000	31,046,000	20,619,000
net decrease in cash, cash equivalents and restricted cash		-44,980,000				-97,029,000			16,141,000	-46,074,000			6,510,000	-153,379,000		-93,337,000	-93,526,000	-329,892,000
acquired in-process research and development											-201,000
amortization of premium (discount) on marketable debt securities																	1,571,000	940,000
non-cash collaboration royalty revenue											-6,058,000	-5,373,000	-5,423,000	-4,838,000	-4,741,000	-4,649,000	-4,689,000	-3,872,000	-3,567,000	-3,331,000	-3,482,000	-2,615,000
deferred tax liabilities
acquisition, net of cash acquired											366,000
proceeds from sale of equity investments															36,646,000
payment for intangible asset						-10,000,000	0	0			0	0	0	-30,000,000
proceeds from the sale of future royalties
proceeds from the issuance of common stock and pre-funded warrants in connection with underwritten public offerings, net of issuance costs
proceeds from the issuance of common stock in connection with at-the-market offering, net of issuances costs
proceeds from the issuance of common stock from exercise of equity plan awards
proceeds from issuance of equity interest in noncontrolling interest
net increase in cash, cash equivalents, and restricted cash
cash, cash equivalents, and restricted cash at beginning of year
cash, cash equivalents, and restricted cash at end of year
other assets				12,718,000	-7,002,000	6,553,000																		70,000	65,000	945,000	-315,000	40,000	157,000	-259,000	30,000	391,000	26,000	75,000	31,000	-422,000	617,000	-1,468,000	139,000	56,000	-9,000	-7,000	-2,234,000	304,000	-579,000	2,098,000
proceeds from issuance of equity from noncontrolling interest
acquired lease liabilities arising from obtaining right-of-use assets and property, plant, and equipment
non-cash interest expense on liabilities for sales of future royalties capitalized during the year into ending property, plant and equipment								1,461,000	4,149,000	3,820,000
contract liabilities							0	0	0	-1,479,000	-1,479,000	-1,479,000	-1,430,000	-3,209,000			-21,177,000	-41,479,000	-36,330,000	-32,000,000	-10,385,000	145,283,000
proceeds from the issuance of common stock from exercise of warrants and equity plan awards															6,924,000	7,674,000	12,742,000	12,761,000	54,242,000	19,193,000	15,478,000	380,000
amortization of (discount) premium on marketable debt securities								-2,681,000	-3,219,000	-2,994,000
costs of pp&e included in ap, accrued, and other liabilities								-4,636,000	-3,074,000	9,137,000
acquired lease liabilities arising from obtaining right-of-use assets												132,000	904,000	132,000		309,000				9,733,000	-3,935,000	7,397,000		0	13,235,000	8,280,000
purchase of equity investments
proceeds from the issuance of common stock in connection with underwritten public offerings																							0	0	0	330,415,000
proceeds from the issuance of common stock in connection with the license agreement																			0	0	0	55,268,000
amortization of premium on marketable debt securities												969,000	1,486,000	1,894,000
non-cash interest expense on liabilities related to the sale of future royalties
proceeds from sale of future royalties
proceeds from the issuance of common stock from equity plan awards												1,074,000	5,983,000	1,755,000
non-cash interest expense on liabilities related to the sale of future royalties capitalized into ending property, plant and equipment
non-cash interest expense on liability related to the sale of future royalties													6,052,000	6,584,000	3,804,000	8,683,000	8,517,000	8,418,000	8,198,000	8,582,000	8,429,000	8,082,000
non-cash interest expense on liability related to the sale of future royalties capitalized into ending property, plant and equipment													2,680,000	2,101,000
purchase of mutual funds related to nonqualified deferred compensation plan														-2,458,000
contract assets and liabilities
receivable related to the daiichi sankyo license agreement																					117,077,000	-125,550,000
purchase of property and equipment																		-16,414,000		-3,780,000	-4,083,000	-14,096,000	-11,500,000	-5,033,000	-5,240,000	-3,059,000	-1,192,000	-1,032,000	-1,377,000	-475,000	-899,000	-1,033,000	-376,000	-485,000	-666,000	-3,001,000	-5,044,000	-1,477,000	-1,923,000	-1,978,000	-595,000	-459,000	-453,000	-439,000	-688,000	-569,000
foreign currency remeasurement (gain) loss																											-544,000	7,000	1,073,000	4,773,000
gain from sale of priority review vouchers																												0
proceeds from sale of equity investment
proceeds from sale of priority review vouchers																											0	0
amortization of premium (discount) on investment securities																											-809,000	-919,000	-674,000	-239,000						1,015,000	1,387,000	1,828,000		1,467,000	1,268,000	965,000		1,048,000	917,000	479,000
foreign currency remeasurement loss																						474,000		358,000	-22,000	589,000
change in fair value of investments in equity securities
right-of-use assets																				-508,000	-1,231,000	-5,522,000		1,619,000	-10,320,000	-6,880,000
lease liabilities																				920,000	1,169,000	5,511,000	-1,519,000	-1,451,000	11,710,000	6,812,000
purchase of investments																				-192,193,000	-171,102,000	-285,229,000	-82,557,000	-149,179,000	-200,354,000	-260,734,000	-9,747,000	-91,366,000	-147,853,000	-260,830,000	3,000	-23,282,000	-119,681,000	-87,527,000	-130,967,000	-88,400,000	-104,993,000	-118,130,000	-146,905,000	-234,917,000	-165,150,000	-77,254,000	-48,030,000	-31,644,000	-41,300,000	-87,998,000
purchase of investments in equity securities
purchase of convertible notes receivable
proceeds from the sale of investments																				11,540,000	12,250,000	16,600,000		12,500,000	0	22,600,000		2,701,000				6,000,000	9,227,000	12,415,000		39,957,000	42,838,000	11,494,000		43,047,000	7,497,000	12,766,000
proceeds from maturities of investments																				93,450,000	86,396,000	187,600,000	153,705,000	221,026,000	161,507,000	140,000,000	84,500,000	105,902,000	51,885,000	60,277,000	70,799,000	48,103,000	89,753,000	64,977,000	77,011,000	103,612,000	91,185,000	131,431,000	90,630,000	49,062,000	47,118,000	62,240,000	29,463,000	15,535,000	14,512,000	23,462,000
payment for intangible assets
principal repayments of financing leases																				-58,000	-58,000	-33,000
amortization of discount on investment securities																					150,000	-299,000		-1,971,000	-2,121,000	-839,000
change in fair value of investment in arcturus equity securities																					-95,200,000	-7,668,000	-1,419,000	-2,166,000
purchase of investment in arcturus equity securities																							0	0
right-of-use lease assets
proceeds from sale of investments
proceeds from the issuance of common stock under equity plan awards
repayment of note payable
supplemental disclosures of non-cash investing and financing information:
acquired lease liabilities arising from obtaining right-of-use lease assets
costs of property and equipment included in accounts payable and other liabilities
fair value of vested stock options assumed in acquisition
prepaid expenses and other current assets																								-2,689,000	-1,906,000	-2,359,000	6,099,000	2,375,000	-17,319,000	-5,063,000	-4,098,000	291,000	-461,000	930,000	-1,314,000	-1,279,000	-526,000	-4,028,000	-736,000	-2,894,000	-2,553,000	-948,000	-382,000	-602,000	-706,000	-2,391,000
accounts payable																								3,910,000	-3,493,000	-151,000	3,965,000	-1,969,000	2,693,000	-1,317,000	-420,000	-2,474,000	3,364,000	2,989,000	-1,340,000	1,017,000	187,000	2,638,000	-1,438,000	-5,321,000	4,340,000	437,000	484,000	733,000	-98,000	2,058,000
accrued liabilities and other liabilities																								7,209,000	9,498,000	-12,930,000	3,276,000	2,752,000	5,544,000	-12,583,000	-3,081,000	4,178,000	6,745,000	-12,470,000	9,601,000	20,406,000	4,051,000	-1,869,000		6,986,000	4,115,000	664,000		1,490,000	2,415,000	-1,186,000
proceeds from the issuance of common stock from equity plan awards, net of tax																								904,000	3,819,000	3,897,000
gain from sale of priority review voucher																														-130,000,000
proceeds from sale of priority review voucher																														130,000,000
gain on sale of priority review voucher
proceeds from the issuance of common stock in connection with collaboration agreement
stock-based compensation capitalized into inventory
costs of property and equipment included in accounts payable and accrued liabilities
tenant improvement allowance
proceeds from issuance of common stock in connection with a public offering																												0	0	270,969,000
proceeds from issuance of common stock in connection with at-the-market offering																												15,837,000	-19,000	11,808,000		0	25,000	67,591,000
proceeds from issuance of common stock from equity awards																												9,187,000	13,187,000	3,642,000		1,333,000	1,501,000	1,378,000
amortization of premium on investment securities																															255,000	400,000	502,000	549,000
non-cash license fee from collaboration arrangement																																			0
decrease (increase) in restricted cash																																											0
net increase in cash and cash equivalents																															40,081,000				18,840,000	87,211,000	-15,694,000	-22,806,000	-73,117,000	114,335,000	-125,689,000	153,716,000	-29,063,000	35,935,000	-37,995,000	48,020,000
cash and cash equivalents at beginning of year
cash and cash equivalents at end of year
foreign currency remeasurement gain																																-3,827,000	-3,956,000	-648,000
increase in restricted cash																																0	1,000	1,220,000	0	341,000	0	-1,543,000		1,071,000	119,000	-1,358,000			0	-293,000
proceeds from issuance of common stock in connection with collaboration agreement
cash and cash equivalents at beginning of period																																0	0	161,120,000		0	0	93,569,000		0	0	24,324,000		0	0	7,427,000
cash and cash equivalents at end of period																																-30,344,000	-68,750,000	159,501,000		87,211,000	-15,694,000	70,763,000		114,335,000	-125,689,000	178,040,000		35,935,000	-37,995,000	55,447,000
net decrease in cash and cash equivalents																																	-68,750,000	-1,619,000
revaluation of convertible preferred stock warrant liability																																											0	0	0	3,324,000
proceeds from the issuance of common stock from equity awards
payment of preferred stock dividend																																											0	0	0	-4,346,000
reclassification of warrant liability to equity upon conversion to common stock warrants
conversion of series a and series b preferred stock to common stock																																											0	0	0	129,360,000
proceeds from issuance of common stock in connection with underwritten public offerings
proceeds from issuance of common stock																																					-25,000	314,000	887,000
accrued expenses and other liabilities
costs of fixed assets included in accounts payable and accrued liabilities
costs of fixed assets included in accounts payable
and accrued liabilities																																								-24,000
reclassification of warrant liability to equity upon conversion to
common stock warrants																																												0	0	6,743,000
proceeds from issuance of common stock, net of issuance costs																																									2,595,000	175,440,000
accrued expenses, deferred rent and other liabilities
proceeds from issuance of convertible preferred stock
proceeds from issuance of promissory notes
issuance of series a redeemable convertible preferred stock in lieu of cash dividend
sale of investments
net proceeds from issuance of common stock, net of issuance costs
net proceeds from issuance of common stock																																													10,000	126,100,000
noncash interest expense
net proceeds from issuance of convertible preferred stock
issuance of convertible preferred stock warrants
issuance of series a redeemable convertible preferred stock in lieu
of cash dividend
conversion of interest accrued on promissory notes into series a
redeemable convertible preferred stock
conversion of promissory notes into series a redeemable
convertible preferred stock

We provide you with 20 years of cash flow statements for Ultragenyx Pharmaceutical stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Ultragenyx Pharmaceutical stock. Explore the full financial landscape of Ultragenyx Pharmaceutical stock with our expertly curated income statements.

The information provided in this report about Ultragenyx Pharmaceutical stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.